Historically, a variety of human epidermal growth factor receptor 2 (HER2)-targeted agents have been studied in NSCLC and it was only more recently that the use of antibody–drug conjugates (ADCs) has shown meaningful benefit in patients with lung cancers harboring HER2 mutations. Here, ERBB2 is linked to lung cancer.